How does rhIGF-I replacement improve insulin sensitivity in insulin dependent diabetes mellitus?

Journal of Pediatric Endocrinology and Metabolism

Volumn 10, Issue SUPPL. 1, 1997, Pages 117-122

  Dunger, D B ^a   Acerini, C L ^a   Cheetham, T D ^a   Crowne, E G ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C RECEPTOR;

CONFERENCE PAPER; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY;

EID: 0030918945     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.1997.10.s1.117     Document Type: Conference Paper

References (44)

1. Froesch ER, Burgi H, Ramseier EB, Bally P, Labhart A. Antibody-suppressible and non-suppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 1963; 42: 1816-1834.
2. Zapf J, Hauri C, Waldvogel M, Froesch ER. Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomised rats. J Clin Invest. 1986; 77: 1786-1775.
3. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor-I in healthy adults. N Engl J Med 1987; 317: 137-140.
4. Dimitriadis G, Parry-Billings M, Piva T, Dunger DB, Bevan S, Wegener G, Krause U, Newsholme E. Effects of insulin like growth factor I on the rates of glucose transport and utilisation in rat skeletal muscle in vitro. Biochem J 1992; 285: 269-274.
5. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor 1 on glucose lipid and amino acid metabolism. Am J Physiol 1992; 262: E130-133.
6. Sherwin RS, Borg WP, Boulware SD. Metabolic effects of insulin-like growth factor I in normal humans. Horm Res 1994; 41 (Suppl 2): 97-102.
7. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglyacemia in patients with extreme insulin resistance. Diabetologia 1991; 34: 675-679.
8. Quin JD, Smith K, Beastall GH, Miell JP, MacGuish AC. The effects of recombinant insulin-like growth factor I on ketone body, lipid and apolipoprotein concentrations and its use to treat ketoacidosis in severe insulin resistance. Diabetic Med 1994; 11: 590-592.
9. Ishihama H, Suzuki Y, Muramatsu K, Nagai M, Kokuko M, Shiraya H, Kawakita A, Nishimura Y, Isamura T, Kobayashi M. Long-term follow up in type A insulin resistant syndrome treated by insulin-like growth factor I. Arch Dis Child 1994; 71: 144-146.
10. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycaemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 1994; 79: 205-210.
11. Zenobi PD, Silvia E, Jaeggi-Groisman S, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241.
12. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler H-P. Adverse effects of recombinant human insulin-like growth factor I in obese insulin resistant type II diabetic patients. Diabetes 1994; 43: 369-374.
13. Cheetham TD, Jones J, Taylor AM, Holly JMP, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor-I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 678-681.
14. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1040-1045.
15. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 1996; 45: 91-100.
16. Dunger DB, Cheetham TD, Holly JMP, Matthews DR. Does recombinant insulin-like growth factor-I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence? Acta Paediatr Scand 1993; (Suppl) 388: 49-52.
17. Edge JA, Dunger DB, Matthews DR, Gilbert JR, Smith CP. Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 1990; 71: 1356-1362.
18. Amiel SA, Sherwin RS, Simonson DV, Laumtano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycaemic control in adolescents with diabetes. N Engl J Med 1986; 315: 215-219.
19. Fowelin J, Attvall S, von Schenck H, Smith U, Lager I. Characterisation of the insulin-antagonistic effect of growth hormone in man. Diabetologia 1991; 34: 500-506.
20. Pal BR, Philips PE, Matthews DR, Dunger DB Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with insulin-dependent diabetes mellitus. Diabetologia 1992; 35: 542-549.
21. Edge JA, Matthews DR, Dunger DB. The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol 1990; 33: 729-737.
22. Perriello G, Defeo P, Torlone E, Fanelli GC, Santeusanio F, Brunetti P, Bolli GB. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahapatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 1990; 33: 52-59.
23. Dunger DB. Insulin and insulin-like growth factors in diabetes mellitus. Arch Dis Child 1995; 72: 469-477.
24. Cheetham TD, Connors M, Clayton K, Watts A, Dunger DB. Insulin senstivity before and after recombinant human insulin-like growth factor I (rhIGF-I) administration in adolescents with IDDM; importance of GH concentrations. Clin Endocrinol (in press).
25. Cheetham TD, Clayton KL, Taylor AM, Holly J, Matthews DR, Dunger DB. The effects of recombinant human insulin-like growth factor I (rhIGF-I) on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994; 40: 515-522.
26. Acerini CL, Umpleby AM, Albany E, Watts A, Russell-Jones DL, Dunger DB. The effect of recombinant IGF-I on glucose metabolism in insulin dependent diabetic patients. Endocrinol Metab 1997; 4(A) 14.
27. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest 1994; 93: 1131-1139.
28. Zapf J, Schoenle E, Waldvogel M, Sand I, Froesch ER. Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 1981; 113: 605-609.
29. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch, ER. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993; 92: 2249-2256.
30. Crowne EC, Samra JS, Acerini C, Cheetham T, Jones J, Holly J, Dunger DB. The role of IGFBP-1 in mediating direct effects of rhIGF-I administration on insulin sensitivity in IDDM. Horm Res 1996; 46 (Suppl 2): 225.
31. Baxter RC, Turtle JR. Regulation of hepatic growth hormone receptors by insulin. Biochem Biophys Res Comm 1978; 84: 350-357.
32. Maes M, Underwood LE, Ketelslegers J-M. Low serum somatomedin-C in insulin-dependent diabetes: evidence for a post receptor mechanism. Endocrinology 1986; 118: 377-382.
33. Arslanian SA, Menon RK, Gierl AP, Heil BV, Foley TP Jr. Insulin therapy increases low plasma growth hormone binding protein in children with new onset type 1 diabetes. Diabetic Med 1993; 10: 833-838.
34. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3 and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab 1994; 79: 872-878.
35. Shisko PI, Kovaler PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes 1992; 41: 1042-1049.
36. Ballard FJ, Baxter RC, Binoux M, et al. Report on the nomenclature of the IGF binding proteins. J Clin Endocrinol Metab 1992; 74: 1215-1216.
37. Bereket A, Lang CH, Blethen SL, Fan J, Frsot RA, Wilson TA. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity. J Clin Endocrinol Metab 1995; 80: 2282-2288.
38. Clemmons DR. IGF binding proteins: regulations of cellular actions. Growth Regul 1992; 2: 80-87.
39. Holly JMP, Biddlecombe RA, Dunger DB, Edge JA, Amiel SA, Howell R, Chard T, Rees LH, Wass JAH. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin? Clin Endocrinol (Oxf) 1988; 29: 667-675.
40. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC. Insulin-like growth factor binding protein-1 modulates blood glucose levels. Endocrinology 1991; 129: 2254-2256.
41. Holly JMP, Dunger DB, Edge JA, Smith CP, Chard T, Wass JAH. Insulin-like growth binding protein-1 (IGFBP-I) levels in diabetic adolescents and their relationship to metabolic control. Diabetic Med 1990; 7: 618-623.
42. Cotterill AM, Daly F, Holly JMP, Cwyfan-Hughes S, Camacho-Hubner C, Abdulla AF, Gale EAM, Savage MO. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Clin Endocrinol 1995; 43: 567-574.
43. Hilding A, Brismar K, Degerblad M, Thoren M, Hall K. Altered relation between circulating levels of insulin-like growth factor binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646-2652.
44. Conover CA, Butler PC, Wang M, Rizza RA, Lee PDK. Lack of growth hormone effect on insulin-associated suppression of insulin-like growth factor binding protein 1 in humans. Diabetes 1990; 39: 1251-1256.